China Hereditary Testing Market Size & Outlook, 2023-2030
China hereditary testing market, 2018-2030 (US$M)
Related Markets
China hereditary testing market highlights
- The China hereditary testing market generated a revenue of USD 491.1 million in 2023 and is expected to reach USD 899.1 million by 2030.
- The China market is expected to grow at a CAGR of 9% from 2024 to 2030.
- In terms of segment, hereditary non-cancer testing was the largest revenue generating disease type in 2023.
- Hereditary Cancer Testing is the most lucrative disease type segment registering the fastest growth during the forecast period.
Hereditary testing market data book summary
| Market revenue in 2023 | USD 491.1 million |
| Market revenue in 2030 | USD 899.1 million |
| Growth rate | 9% (CAGR from 2023 to 2030) |
| Largest segment | Hereditary non-cancer testing |
| Fastest growing segment | Hereditary Cancer Testing |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
| Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
Other key industry trends
- In terms of revenue, China accounted for 6.8% of the global hereditary testing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China hereditary testing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 417.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hereditary Testing Market Scope
Hereditary Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China hereditary testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 84.95% in 2023. Horizon Databook has segmented the China hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
China has successfully embraced advancements in genetic testing, with increasing adoption of DTC tests, expansion of NGS technologies, and a substantial number of companies offering genetic testing services. For instance, in June 2017, Veritas Genetics, a U.S. based company, launched the first wholegenome newborn screening test in China, known as myBabyGenome.
This test empowered physicians and parents to make better decisions about childhood-onset diseases and medications. This solution decodes complete genomes of infants at USD 1,500 and provides data on 950 serious early & adultstage disease risks, with over 100 physical traits and 200 genes related to drug reactions in newborns. This product introduction expanded newborn sequencing market in China.
Reasons to subscribe to China hereditary testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China hereditary testing market databook
-
Our clientele includes a mix of hereditary testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into China hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China hereditary testing market size, by disease type, 2018-2030 (US$M)
China Hereditary Testing Market Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
